Preliminary clinical results of innovative TCR immunotherapy combination for treating melanoma are positive

Recently, Immunocore announced that it will demonstrate its T-cell receptor therapy tebentafusp combined with PD-L1 inhibitor durvalumab and/or CTLA4 inhibitor tremelimumab at the 36th annual meeting of the Society for Cancer Immunotherapy (SITC) in the treatment of metastatic skin melanoma (MCM) Phase 1b clinical trial results

Tebentafusp is a bispecific molecule

It is worth noting that the company's corresponding technology allows TCR to recognize cancer antigens in cells with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of recognizable targets from 10% to 90%

▲The design of this type of TCR therapy mimics the natural TCR mechanism of action (picture source: Immunocore company official website)

In this phase 1b trial, most patients have previously been treated with anti-PD-1 or PD-L1 inhibitors

Note: The original text has been deleted

Reference materials:

[1] Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.